Muromonab  (Synonyms: Muromanab-CD3)

Muromonab (Muromonab-CD3; OKT3) is a mouse monoclonal antibody targeting the CD3 antigen. Muromonab specifically binds to the CD3 antigen on the surface of human and higher primate T cells. Muromonab blocks the function of T cell receptors to recognize foreign antigens and inhibits T cell-mediated immune responses, including cell-mediated lymphocyte lysis and T cell proliferation responses. Muromonab can be used to study acute kidney, liver, heart and combined kidney-pancreas transplant rejection, and can also be used to study graft-versus-host disease in bone marrow transplant patients^{[1][2][3][4][5]}.

Muromonab blocks cytotoxic T cell function and inhibits T cell proliferation^[1].
Muromonab binds to the CD3 antigen on T cells, resulting in rapid clearance/depletion of CD3⁺ T cells in the extracorporeal circulation and reduction of CD4⁺ and CD8⁺ subsets^[1].
Muromonab blocks both the induction and effector phases of cell-mediated lympholysis, inhibits T cell proliferation in response to major histocompatibility complex antigens, and modulates CD3 antigen expression on the surface of T cells.^[1]
Muromonab also induces the release of cytokines such as IL-2 and IFN-γ, thereby promoting the production of early immune activation markers^[1].
Curcumin (HY-N0005) and Sirolimus (HY-10219) inhibit muromonab-induced human peripheral blood mononuclear cell (PBMC) proliferation in a concentration-dependent manner (IC₅₀=2.8 μM and 1.1 ng/mL), respectively, and their combined use at low concentrations had a synergistic effect^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Muromonab significantly prolonged kidney graft survival and inhibited acute rejection in a macaque kidney transplant model^[1].
The average steady-state plasma trough concentration of Muromonab (5 mg; intravenous injection; 2-3 times) is approximately 0.9 mg/L, a plasma concentration that has the function of blocking cytotoxic T cells^[1].
Muromonab (0.1 mg/kg/day; intravenous; 10-14 days) causes massive lymphocyte depletion^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

146.34 kDa

140608-64-6

Liquid

Colorless to light yellow

[Muromonab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG2a-G1-kappa

• [1]. P A Todd, et al. Muromonab CD3. A review of its pharmacology and therapeutic potential. Drugs. 1989 Jun;37(6):871-99.  [Content Brief]

  [2]. Lahdou I, et al. Role of human corneal endothelial cells in T-cell-mediated alloimmune attack in vitro. Invest Ophthalmol Vis Sci. 2014 Mar 3;55(3):1213-21.  [Content Brief]

  [3]. Yan H, et al. Bone marrow-liver-thymus (BLT) immune humanized mice as a model to predict cytokine release syndrome. Transl Res. 2019 Aug;210:43-56.  [Content Brief]

  [4]. Ménoret S, et al. Efficient generation of human immune system rats using human CD34+ cells. Stem Cell Reports. 2024 Sep 10;19(9):1255-1263.  [Content Brief]

  [5]. OKT 3. Sciencedirect.

  [6]. Deters M, et al. Synergistic immunosuppressive effects of the mTOR inhibitor sirolimus and the phytochemical curcumin. Phytomedicine. 2013 Jan 15;20(2):120-3.  [Content Brief]